etoposide has been researched along with Cardiometabolic Syndrome in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Altena, R; Boer, H; Boezen, HM; Dijck-Brouwer, DAJ; Gietema, JA; Kema, IP; Klont, F; Lefrandt, JD; Meijer, C; Nuver, J; Smit, AJ; van Faassen, M; Westerink, NL; Zwart, N | 1 |
1 other study(ies) available for etoposide and Cardiometabolic Syndrome
| Article | Year |
|---|---|
Single-nucleotide polymorphism in the 5-α-reductase gene (SRD5A2) is associated with increased prevalence of metabolic syndrome in chemotherapy-treated testicular cancer survivors.
Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; Adolescent; Adult; Albuminuria; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bleomycin; Carotid Artery Diseases; Cisplatin; Cross-Sectional Studies; Etoposide; Gene Frequency; Heterozygote; Homozygote; Humans; Male; Membrane Proteins; Metabolic Syndrome; Middle Aged; Netherlands; Phenotype; Polymorphism, Single Nucleotide; Prevalence; Risk Factors; Survivors; Testicular Neoplasms; Testosterone; Time Factors; Treatment Outcome; Young Adult | 2016 |